Home Cart 0 Sign in  

[ CAS No. 13515-93-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 13515-93-0
Chemical Structure| 13515-93-0
Structure of 13515-93-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 13515-93-0 ]

Related Doc. of [ 13515-93-0 ]

Alternatived Products of [ 13515-93-0 ]

Product Details of [ 13515-93-0 ]

CAS No. :13515-93-0 MDL No. :MFCD00038876
Formula : C4H10ClNO2 Boiling Point : -
Linear Structure Formula :- InChI Key :HQZMRJBVCVYVQA-UHFFFAOYSA-N
M.W : 139.58 Pubchem ID :83544
Synonyms :
Methyl N-methylglycinate hydrochloride

Calculated chemistry of [ 13515-93-0 ]

Physicochemical Properties

Num. heavy atoms : 8
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.75
Num. rotatable bonds : 3
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 32.39
TPSA : 38.33 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.78 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 0.52
Log Po/w (WLOGP) : 0.18
Log Po/w (MLOGP) : 0.01
Log Po/w (SILICOS-IT) : -0.35
Consensus Log Po/w : 0.07

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 2.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.84
Solubility : 20.4 mg/ml ; 0.146 mol/l
Class : Very soluble
Log S (Ali) : -0.9
Solubility : 17.7 mg/ml ; 0.127 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -0.73
Solubility : 26.2 mg/ml ; 0.188 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.03

Safety of [ 13515-93-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 13515-93-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 13515-93-0 ]
  • Downstream synthetic route of [ 13515-93-0 ]

[ 13515-93-0 ] Synthesis Path-Upstream   1~10

  • 1
  • [ 13515-93-0 ]
  • [ 20353-93-9 ]
  • [ 17289-20-2 ]
  • [ 40637-81-8 ]
Reference: [1] Synthesis, 1994, # 3, p. 247 - 248
  • 2
  • [ 13515-93-0 ]
  • [ 1611-78-5 ]
  • [ 37619-24-2 ]
Reference: [1] Tetrahedron Letters, 2010, vol. 51, # 31, p. 4150 - 4152
  • 3
  • [ 24424-99-5 ]
  • [ 13515-93-0 ]
  • [ 42492-57-9 ]
YieldReaction ConditionsOperation in experiment
90% With triethylamine In dichloromethane at 0 - 20℃; for 48 h; Inert atmosphere To a suspension of sarcosine (35.64 g, 0.40 mol) in 350 mL MeOH was added thionyl chloride (29.02 mL, 0.40 mol) dropwise at 0 °C. After complete addition the cooling bath was removed and the reaction mixture was stirred for 30 min at r.t. and refluxed for further 6 h. The resulting solution was concentrated in vacuum and the residue was dried in high vacuum over night at r.t. to afford sarcosine methyl ester.HCl as a white powder which was used in the next step without further purification; yield: 56.14 g (quant.); mp. 102 °C. 1H-NMR (300 MHz, CDCl3): δ = 9.76 (s, 2 H, NH2), 3.88 (t, J = 5.6 Hz, 2 H, H-2), 3.82 (s, 3 H, H-4)), 2.83 (t, J = 5.2 Hz, 3 H, H-3). 13C-NMR(75 MHz, CDCl3): δ = 166.7 (C-1), 53.3 (C-2), 48.9 (C-3), 33.4 (C-4).1 To a suspension of sarcosine methylester.HCl (59.80 g, 0.43 mol) and (Boc)2O (138.01 mL, 0.65 mol) in 1.0 L CH2Cl2 TEA (119.09 mL, 0.86 mol) was added dropwise at 0 °C. After complete addition the cooling bath was removed and the reaction mixture was stirred for two days at r.t. Aq. HCl (1 M) was added until the aqueous layer showed pH = 6. The resulting two layers were separated and the organic layer was washed with dist. H2O, dried (Na2SO4), concentrated in vacuum and volatile impurities were removed in high vacuum over night at r.t. to afford a clear oil; yield: 78.65 g (90 percent)
Reference: [1] Synthesis (Germany), 2017, vol. 49, # 4, p. 770 - 774
[2] Patent: EP1032561, 2004, B1, . Location in patent: Page 21
  • 4
  • [ 1070-19-5 ]
  • [ 13515-93-0 ]
  • [ 42492-57-9 ]
Reference: [1] Gazzetta Chimica Italiana, 1977, vol. 107, p. 381 - 385
  • 5
  • [ 42492-57-9 ]
  • [ 13515-93-0 ]
YieldReaction ConditionsOperation in experiment
100% With hydrogenchloride In 1,4-dioxane; dichloromethane at 0 - 20℃; for 1 h; General procedure: A solution of HCl (3.3 M) in dioxane (5 mL) was added to a stirred solution of Nα-Boc-protected peptide (1 mmol) in DCM (2 mL) at 0 °C. The temperature was risen to 20 °C and the solution maintained for 1 h. The solvents were removed under vacuum and the residue stirred in dry ether to produce a crystalline product. In case of the poorly crystallizing or highly hygroscopic compounds the residual material was dissolved in dry chloroform, the solution evaporated and the product dried in a vacuum desiccator over P4O10 or KOH. Some products were purified by chromatography using silica gel and eluent mixture B, or by gel filtration on biogel P2 or fractogel TCK HW 40 with subsequent lyophilization.
Reference: [1] Tetrahedron, 2012, vol. 68, # 35, p. 7070 - 7076
  • 6
  • [ 67-56-1 ]
  • [ 107-97-1 ]
  • [ 13515-93-0 ]
YieldReaction ConditionsOperation in experiment
100% for 6.5 h; Cooling; Reflux; Inert atmosphere To a suspension of sarcosine (35.64 g, 0.40 mol) in 350 mL MeOH was added thionyl chloride (29.02 mL, 0.40 mol) dropwise at 0 °C. After complete addition the cooling bath was removed and the reaction mixture was stirred for 30 min at r.t. and refluxed for further 6 h. The resulting solution was concentrated in vacuum and the residue was dried in high vacuum over night at r.t. to afford sarcosine methyl ester.HCl as a white powder which was used in the next step without further purification; yield: 56.14 g (quant.);
Reference: [1] Synthesis (Germany), 2017, vol. 49, # 4, p. 770 - 774
[2] Chemical and Pharmaceutical Bulletin, 1989, vol. 37, # 9, p. 2398 - 2405
[3] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1981, p. 529 - 537
[4] Synthesis, 1988, # 10, p. 767 - 771
[5] Liebigs Annalen der Chemie, 1984, vol. 1984, # 10, p. 1672 - 1684
[6] Organic and Biomolecular Chemistry, 2008, vol. 6, # 9, p. 1594 - 1600
[7] Bulletin de la Societe Chimique de France, 1993, vol. 130, p. 584 - 596
[8] Archiv der Pharmazie, 2011, vol. 344, # 8, p. 494 - 504
[9] Heterocycles, 1991, vol. 32, # 10, p. 1879 - 1895
[10] Archiv der Pharmazie, 1992, vol. 325, # 11, p. 709 - 715
[11] Journal of Chemical Research, Miniprint, 1984, # 8, p. 2230 - 2253
  • 7
  • [ 107-97-1 ]
  • [ 13515-93-0 ]
Reference: [1] Patent: US5066784, 1991, A,
  • 8
  • [ 67-56-1 ]
  • [ 13515-93-0 ]
Reference: [1] Beilstein Journal of Organic Chemistry, 2012, vol. 8, p. 1105 - 1111
  • 9
  • [ 107-97-1 ]
  • [ 74-88-4 ]
  • [ 13515-93-0 ]
Reference: [1] Bulletin of the Chemical Society of Japan, 2004, vol. 77, # 6, p. 1187 - 1193
  • 10
  • [ 67-56-1 ]
  • [ 238090-53-4 ]
  • [ 13515-93-0 ]
Reference: [1] Journal of Physical Organic Chemistry, 2004, vol. 17, # 5, p. 448 - 457
Same Skeleton Products
Historical Records

Similar Product of
[ 13515-93-0 ]

Chemical Structure| 945218-53-1

A1268115[ 945218-53-1 ]

Sarcosine-13C3, 15N methyl ester hydrochloride

Reason: Stable Isotope

Related Functional Groups of
[ 13515-93-0 ]

Amino Acid Derivatives

Chemical Structure| 39987-25-2

[ 39987-25-2 ]

Dimethyl 2,2'-azanediyldiacetate hydrochloride

Similarity: 0.96

Chemical Structure| 52605-49-9

[ 52605-49-9 ]

Ethyl 2-(methylamino)acetate hydrochloride

Similarity: 0.93

Chemical Structure| 6290-05-7

[ 6290-05-7 ]

Diethyl 2,2'-azanediyldiacetate

Similarity: 0.86

Chemical Structure| 5680-79-5

[ 5680-79-5 ]

H-Gly-OMe.HCl

Similarity: 0.84

Chemical Structure| 136088-69-2

[ 136088-69-2 ]

tert-Butyl 2-(methylamino)acetate hydrochloride

Similarity: 0.78